Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Duzallo Approval Opens Gout Opportunity For Ironwood

Executive Summary

Pricing for Duzallo, a fixed-dose combination of Zurampic (lesinurad) with generic allopurinol, will likely be on par with Zurampic's solo price tag of $371 per month to smooth the way with payers.

Advertisement

Related Content

Ironwood Pulls Plug On Struggling Gout Drug Zurampic
Ironwood Puts It Bluntly: Denner Lacks Case To Join Board, Wouldn’t Provide Missing Insight
ACR Notebook: Lilly's Baricitinib Differentiates On Pain, Ironwood's Duzallo Progress, Corbus Nears Phase III
US Approvals Roundup: Cyltezo Biosimilar, Victoza CV Benefit, Gocovri In PD, Kedrab Rabies Biologic, Gout Combo Duzallo
US Approvals Roundup: Cyltezo Biosimilar, Victoza CV Benefit, Gocovri In PD, Kedrab Rabies Biologic, Gout Combo Duzallo
Keeping Track: New Indication For Lucentis; New Lesinurad Application From Ironwood
With Zurampic, FDA Again Made Do With Sorry State Of Regulatory Science In Gout
Ironwood Buys AstraZeneca's Zurampic As Ideal Linzess Complement
As Gout Market Opens Up, Experts Await Therapies To Better Lower Uric Acid

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099349

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel